ProCE Banner Activity

Single-Agent PARP Inhibitors in Prostate Cancer

Slideset

Download this slideset from a live symposium to learn more about HRR mutations and PARP inhibitor monotherapy in metastatic prostate cancer.

Released: January 24, 2024

Share

Faculty

Andrew Armstrong

Andrew Armstrong, MD, ScM, FACP

Professor of Medicine, Surgery, Pharmacology and Cancer Biology
Director of Research
The Duke Cancer Institute Center for Prostate and Urologic Cancers
Divisions of Medical Oncology and Urology
Duke University
Durham, North Carolina

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Merck & Co., Inc., Rahway, NJ, USA.

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck & Co., Inc., Rahway, NJ, USA